AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Tealwood Asset Management Inc.

Tealwood Asset Management Inc. lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.8% during the fourth quarter, HoldingsChannel.com reports. The firm owned 37,410 shares of the company’s stock after purchasing an additional 290 shares during the period. Tealwood Asset Management Inc.’s holdings in AstraZeneca were worth $2,451,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Stratos Wealth Advisors LLC boosted its holdings in AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after buying an additional 133 shares in the last quarter. Crumly & Associates Inc. boosted its stake in shares of AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock worth $518,000 after acquiring an additional 143 shares in the last quarter. Harbour Investments Inc. raised its holdings in AstraZeneca by 1.9% during the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after purchasing an additional 160 shares during the last quarter. Smith Salley Wealth Management boosted its position in AstraZeneca by 1.0% during the third quarter. Smith Salley Wealth Management now owns 16,158 shares of the company’s stock worth $1,259,000 after purchasing an additional 162 shares in the last quarter. Finally, Veracity Capital LLC grew its holdings in AstraZeneca by 4.5% in the third quarter. Veracity Capital LLC now owns 3,833 shares of the company’s stock valued at $299,000 after purchasing an additional 164 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

NASDAQ:AZN opened at $65.73 on Tuesday. The firm has a market cap of $203.80 billion, a price-to-earnings ratio of 31.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.46. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The company’s 50-day moving average is $66.00 and its two-hundred day moving average is $74.78.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.87 earnings per share. Research analysts expect that AstraZeneca PLC will post 4.11 EPS for the current year.

Analysts Set New Price Targets

AZN has been the subject of several research reports. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.